Literature DB >> 8101839

A signal transduction pathway for activation of the mdr1 promoter involves the proto-oncogene c-raf kinase.

M M Cornwell1, D E Smith.   

Abstract

To investigate the regulation of expression of the human mdr1 gene, the response of the mdr1 promoter to signals involved in cell proliferation was examined. The activity of the mdr1 promoter was measured in transiently transfected NIH 3T3 cells, which were stimulated to enter the cell cycle by addition of serum, platelet-derived growth factor, or transforming growth factor alpha. Addition of serum to quiescent NIH 3T3 cells resulted in a 6-8-fold activation of mdr1 promoter activity, which peaked at 10 h, just prior to S-phase. Treatment of serum-starved cells with the serum mitogens platelet-derived growth factor and transforming growth factor alpha also activated the mdr1 promoter. To define components of the signal cascade resulting in mdr1 promoter activation, the role of c-Raf kinase, a serine/threonine kinase important in mitogen-activated signal transduction, was examined. We measured the effects of a constitutively activated Raf kinase, v-raf, and a dominant negative Raf mutant, c-Raf-C4, on mdr1 promoter activity in NIH 3T3 and HepG2 cells. In serum-starved NIH 3T3 cells, v-raf increased mdr1 promoter activity approximately 10-fold compared to a v-raf frame-shift control. Raf responsiveness of the mdr1 promoter was localized to sequences between -69 and -41, relative to the initiation site. Serum stimulation of the mdr1 promoter was blocked by co-transfection of NIH 3T3 cells with the dominant negative Raf mutant c-Raf-C4. In the human hepatoma cell line HepG2, which has high endogenous Raf kinase activity (Bruder, J. T., Heidecker, G., and Rapp, U. R. (1992) Genes & Dev. 6, 545-556), co-transfection with c-Raf-C4 decreased mdr1 promoter activity 20-fold. Taken together, these data suggest that the mdr1 gene is transcriptionally regulated by normal cellular signaling events involving activation of c-Raf kinase.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8101839

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  13 in total

1.  Genetic variations in multiple drug action pathways and survival in advanced stage non-small cell lung cancer treated with chemotherapy.

Authors:  Yafei Li; Zhifu Sun; Julie M Cunningham; Marie C Aubry; Jason A Wampfler; Gary A Croghan; Cassandra Johnson; Danli Wu; Jeremiah A Aakre; Julian Molina; Liewei Wang; V Shane Pankratz; Ping Yang
Journal:  Clin Cancer Res       Date:  2011-06-01       Impact factor: 12.531

Review 2.  Molecular pathways: regulation and therapeutic implications of multidrug resistance.

Authors:  Kevin G Chen; Branimir I Sikic
Journal:  Clin Cancer Res       Date:  2012-02-16       Impact factor: 12.531

3.  p53-dependent regulation of MDR1 gene expression causes selective resistance to chemotherapeutic agents.

Authors:  J V Thottassery; G P Zambetti; K Arimori; E G Schuetz; J D Schuetz
Journal:  Proc Natl Acad Sci U S A       Date:  1997-09-30       Impact factor: 11.205

Review 4.  Biochemical, genetic, and metabolic adaptations of tumor cells that express the typical multidrug-resistance phenotype. Reversion by new therapies.

Authors:  L G Baggetto
Journal:  J Bioenerg Biomembr       Date:  1997-08       Impact factor: 2.945

5.  Phase II trial of tipifarnib plus neoadjuvant doxorubicin-cyclophosphamide in patients with clinical stage IIB-IIIC breast cancer.

Authors:  Joseph A Sparano; Stacy Moulder; Aslamuzzaman Kazi; Domenico Coppola; Abdissa Negassa; Linda Vahdat; Tianhong Li; Christine Pellegrino; Susan Fineberg; Pam Munster; Mokenge Malafa; David Lee; Shira Hoschander; Una Hopkins; Dawn Hershman; John J Wright; Celina Kleer; Sofia Merajver; Said M Sebti
Journal:  Clin Cancer Res       Date:  2009-04-07       Impact factor: 12.531

Review 6.  Modulation of tumor cell response to chemotherapy by the organ environment.

Authors:  I J Fidler; C Wilmanns; A Staroselsky; R Radinsky; Z Dong; D Fan
Journal:  Cancer Metastasis Rev       Date:  1994-06       Impact factor: 9.264

7.  Phase I-II study of the farnesyl transferase inhibitor tipifarnib plus sequential weekly paclitaxel and doxorubicin-cyclophosphamide in HER2/neu-negative inflammatory carcinoma and non-inflammatory estrogen receptor-positive breast carcinoma.

Authors:  Eleni Andreopoulou; Ivette S Vigoda; Vicente Valero; Dawn L Hershman; George Raptis; Linda T Vahdat; Hyo S Han; John J Wright; Christine M Pellegrino; Massimo Cristofanilli; Ricardo H Alvarez; Karen Fehn; Susan Fineberg; Joseph A Sparano
Journal:  Breast Cancer Res Treat       Date:  2013-09-26       Impact factor: 4.872

8.  Drug-induced changes in the expression of MDR-associated genes: investigations on cultured cell lines and chemotherapeutically treated leukemias.

Authors:  V Gekeler; J Beck; A Noller; A Wilisch; G Frese; M Neumann; R Handgretinger; G Ehninger; H Probst; D Niethammer
Journal:  Ann Hematol       Date:  1994       Impact factor: 3.673

9.  The enhancement of Raf-1 kinase activity by knockdown of Spry2 is associated with high sensitivity to paclitaxel in v-Ha-ras-transformed NIH 3T3 fibroblasts.

Authors:  Jun-Ho Ahn; Ki-Hwan Eum; Michael Lee
Journal:  Mol Cell Biochem       Date:  2009-07-09       Impact factor: 3.396

Review 10.  Role of protein kinases in antitumor drug resistance.

Authors:  H Grunicke; J Hofmann; I Utz; F Uberall
Journal:  Ann Hematol       Date:  1994       Impact factor: 3.673

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.